Co-prescribing study shows need to lower risk of drug interactions with DOACs

The potential for drug interactions with DOACs in patients with atrial fibrillation (AF) has decreased slightly in recent years, but there is still room for improvement in the co-prescribing of DOACs and medications which may decrease their safety and efficacy. An Australian study interrogating the national GP dataset examined trends in the co-prescribing of DOACs ...

Already a member?

Login to keep reading.

© 2021 the limbic